Cargando…

The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy

PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localize...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qifeng, Li, Tao, Liu, Huiming, Jia, Xitang, Liu, Bo, Wan, Xin, Lang, Jinyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016616/
https://www.ncbi.nlm.nih.gov/pubmed/24774780
http://dx.doi.org/10.1186/1748-717X-9-99
_version_ 1782315533507493888
author Wang, Qifeng
Li, Tao
Liu, Huiming
Jia, Xitang
Liu, Bo
Wan, Xin
Lang, Jinyi
author_facet Wang, Qifeng
Li, Tao
Liu, Huiming
Jia, Xitang
Liu, Bo
Wan, Xin
Lang, Jinyi
author_sort Wang, Qifeng
collection PubMed
description PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and 29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22. RESULTS: The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were 57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and 146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation. CONCLUSION: A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused more severe esophageal injury.
format Online
Article
Text
id pubmed-4016616
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40166162014-05-11 The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy Wang, Qifeng Li, Tao Liu, Huiming Jia, Xitang Liu, Bo Wan, Xin Lang, Jinyi Radiat Oncol Research PURPOSE: To assess the safety and usefulness of neutron brachytherapy (NBT) as an adjuvant in the treatment of patients with gastroesophageal junction adenocarcinoma (GEJAC) with external beam radiation (EBRT), with or without chemotherapy. METHODS AND MATERIALS: In total, 197 patients with localized, advanced GEJAC received EBRT and NBT with or without chemotherapy. Radiotherapy consisted of external irradiation to a total dose of 40–54 Gy (median 50 Gy) and brachytherapy to 8–25 Gy (median 20 Gy) in two to five fractions. In total, 88 patients received chemotherapy that consisted of two cycles of a regimen with CDDP and 5FU from days l-4. The cycles were administered on days 1 and 29. MMC was given alone in bolus injection on day 1 each week. The cycles were administered on days 1, 8, 15 and 22. RESULTS: The duration of follow-up ranged from six to 106 months (median 30.4 months). The median survival time for the 197 patients was 13.3 months, and the one, two, three- and five-year rates for overall survival were 57.1%, 35.1%, 23.0% and 9.2%, respectively. For acute toxicity, no incidences of fistula and massive bleeding were observed during this treatment period. In total, 159 (80.7%) patients developed Grade 2 hematologic toxicity and 146 (74.1%) patients developed Grade ≥ 2 esophagitis. The median times of incidence of fistula and bleeding were 9.5 (3–27.3) months and 12.7 (5–43.4) months, respectively. The incidence of severe, late complications was related to higher NBT dose/f (20–25 Gy/5 F) and higher total dose(≥70 Gy). In total, 75.2% of the patients resumed normal swallowing and 2.0% had some residual dysphagia (non-malignant) requiring intermittent dilatation. CONCLUSION: A combination of EBRT and NBT with the balloon type applicator was feasible and well tolerated. Better local-regional control and overall survival cannot achieved by a higher dose, and in contrast, a higher dose caused more severe esophageal injury. BioMed Central 2014-04-29 /pmc/articles/PMC4016616/ /pubmed/24774780 http://dx.doi.org/10.1186/1748-717X-9-99 Text en Copyright © 2014 Wang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Wang, Qifeng
Li, Tao
Liu, Huiming
Jia, Xitang
Liu, Bo
Wan, Xin
Lang, Jinyi
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title_full The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title_fullStr The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title_full_unstemmed The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title_short The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
title_sort safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016616/
https://www.ncbi.nlm.nih.gov/pubmed/24774780
http://dx.doi.org/10.1186/1748-717X-9-99
work_keys_str_mv AT wangqifeng thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT litao thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT liuhuiming thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT jiaxitang thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT liubo thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT wanxin thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT langjinyi thesafetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT wangqifeng safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT litao safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT liuhuiming safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT jiaxitang safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT liubo safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT wanxin safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy
AT langjinyi safetyandusefulnessofneutronbrachytherapyandexternalbeamradiationinthetreatmentofpatientswithgastroesophagealjunctionadenocarcinomawithorwithoutchemotherapy